Joint Disease Clinical Trial
Official title:
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components
Verified date | July 2022 |
Source | MicroPort Orthopedics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.
Status | Active, not recruiting |
Enrollment | 121 |
Est. completion date | June 2027 |
Est. primary completion date | June 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Has undergone primary THA for any of the following: - Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; - Inflammatory degenerative joint disease such as rheumatoid arthritis; or - Correction of functional deformity - Subject is implanted with the specified combination of components - Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs enrolled in the study provided: - the specified combination of components were implanted in both - all other aspects of the Inclusion/Exclusion Criteria are satisfied - enrollment does not exceed the subject count specified in the Clinical Trial Agreement - the subject agrees to a second Informed Consent document specific to the second THA. Exclusion Criteria: - Subjects implanted with a metal-on-metal articulation - Subjects implanted with non-MPO or non-Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners) at the time of their primary THA in the enrolled THA - Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery - Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol - Subjects unwilling to sign the Informed Consent document - Subjects with substance abuse issues - Subjects who are incarcerated or having pending incarceration |
Country | Name | City | State |
---|---|---|---|
Germany | Elbe Kliniken Buxtehude | Buxtehude |
Lead Sponsor | Collaborator |
---|---|
MicroPort Orthopedics Inc. |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Component Survivorship | The primary objective of this study is to estimate survivorship analysis of all components at specified intervals out to 10 years follow-up. | 10 years post-operative | |
Secondary | Patient functional outcomes (hip specific) | To characterize total functional scores, as assessed by Oxford Hip Scores | 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit | |
Secondary | Patient functional outcomes (quality of life) | To characterize total functional scores, as assessed by EQ-5D-3L scores | 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02314702 -
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems
|
||
Completed |
NCT03271151 -
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT03272139 -
Interscalene Block Versus Superior Trunk Block
|
Phase 4 | |
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01256216 -
Signature Versus Computer Assisted Surgery Study
|
N/A | |
Completed |
NCT03337243 -
Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis
|
N/A | |
Active, not recruiting |
NCT03294408 -
Multimodal Imaging of Subchondral Bone in Knee Osteoarthritis : Predictive Model
|
N/A | |
Withdrawn |
NCT02668211 -
Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components
|
N/A | |
Active, not recruiting |
NCT02239783 -
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
|
||
Terminated |
NCT00698347 -
A Clinical Investigation of the M2a-Magnumâ„¢ Hip System
|
N/A | |
Completed |
NCT00223353 -
Quantitative Gait Analysis for Clinical Decision Making
|
N/A | |
Recruiting |
NCT04037735 -
RSA-RCT: Attune S+ TKA Versus Sigma TKA
|
N/A | |
Terminated |
NCT03575975 -
3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty
|
||
Completed |
NCT03894514 -
Multi-variable Prediction Model of Total Knee Replacement Outcome
|
||
Completed |
NCT02865447 -
Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis
|
||
Enrolling by invitation |
NCT03576573 -
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components
|
||
Completed |
NCT02967874 -
Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT02390336 -
Mobilization With Movement in Patients With Osteoarthritis of the Hip
|
N/A | |
Terminated |
NCT03293719 -
Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
|
||
Active, not recruiting |
NCT02351414 -
Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts
|